InflaRx N.V. - ADR

Name: InflaRx N.V. - ADR Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: InflaRx N.V. - ADR

Stock Card

$2.27

$-0.15 (-6.20%)

As on 27-Aug-2026 16:00EDT

Market cap

$309 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

1.8

Div. Yield

0 %

Value Research Rating

Quality Score

Growth Score

Valuation Score

Momentum Score

Know more

Explore 5 star rated stocks

InflaRx N.V. - ADR Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 2.25 High: 2.43

52 Week Range

Low: 0.80 High: 2.94

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.4 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

0.5
Debt to Equity

0
Book Value

$--
EPS

$-0.5
Face value

--
Shares outstanding

147,368,221

9 Years Aggregate

CFO

€-234.61 Mln

EBITDA

€-297.26 Mln

Net Profit

€-266.15 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
InflaRx N.V. - ADR	124.8	30.5	-17.2	146.7	-14.7	-1.9	--
BSE Sensex^*	-8.8	0.5	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 27-Aug-2026 | *As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2025	2023	2022	2021	2020	2019
InflaRx N.V. - ADR	-59.1	-47.4	-34.9	-5.4	27.0	-89.1
S&P Small-Cap 600	4.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About InflaRx N.V. - ADR

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory... diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications. It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany. Read more

Co-Founder, CEO & Executive Director

Dr. Niels C. Riedemann M.D., Ph.D.
Co-Founder, CEO & Executive Director

Dr. Niels C. Riedemann M.D., Ph.D.
Headquarters

Jena
Website

https://www.inflarx.de

FAQs for InflaRx N.V. - ADR

What is the current share price of InflaRx NV - ADR Today?

The share price of InflaRx NV - ADR is $2.27 (NASDAQ) as of 27-Aug-2026 16:00 EDT. InflaRx NV - ADR has given a return of -14.72% in the last 3 years.

What is the current PB & PE ratio of InflaRx NV - ADR?

Since, TTM earnings of InflaRx NV - ADR is negative, P/E ratio is not available.
The P/B ratio of InflaRx NV - ADR is 1.76 times as on 21-Aug-2026, a 49 discount to its peers’ median range of 3.48 times.

PE & PB ratio at the end of financial year.